Table 1 Characteristics of patients with and without delayed MTX elimination
Indictors | All Cohorts (n = 1729) | Training Cohorts (n = 1210) | p | ||
|---|---|---|---|---|---|
Without metabolic delay (n = 1400) | With metabolic delay (n = 329) | Without metabolic delay (n = 980) | With metabolic delay (n = 230) | ||
Baseline information | |||||
Age (year) | 9.0 (8.0–13.0) | 11.0 (9.0–14.0) | 9.0 (8.0–13.0) | 11.0 (9.0-14.3) | < 0.001 |
Weight (kg) | 17.5 (14.0–25.0) | 22.0 (16.0–30.0) | 17.0 (14.0-25.5) | 22.5 (16.0–31.0) | < 0.001 |
Sex | |||||
Male | 810 (57.86) | 200 (60.79) | 562 (57.35) | 138 (60.00) | 0.510 |
Female | 590 (42.12) | 129 (39.21) | 418 (42.65) | 92 (40.00) | |
Clinical features | |||||
Emesis | 22 (1.57) | 2 (0.61) | 964 (98.37) | 230 (100.00) | 0.103 |
Hydrops | 41 (2.93) | 7 (2.13) | 948 (96.73) | 226 (98.26) | 0.312 |
Cell Morphological Classification | |||||
L1 | 518 (0.37) | 118 (35.87) | 362 (36.94) | 89 (38.70) | 0.048 |
L2 | 788 (56.29) | 202 (61.40) | 550 (56.12) | 135 (58.70) | |
L3 | 94 (6.71) | 9 (2.74) | 68 (6.94) | 6 (2.61) | |
ALL risk level | |||||
Standard risk | 3 (0.21) | 0 (0.00) | 2 (0.20) | 0 (0.00) | < 0.001 |
Low risk | 836 (59.71) | 122 (37.08) | 591 (60.31) | 88 (38.26) | |
Intermediate risk | 523 (37.36) | 205 (62.31) | 363 (37.04) | 140 (60.87) | |
High risk | 38 (2.71) | 2 (0.61) | 24 (2.45) | 2 (0.87) | |
Immunological Classification | |||||
B-ALL | 1306 (93.29) | 280 (85.11) | 914 (93.27) | 198 (86.09) | < 0.001 |
T-ALL | 94 (6.71) | 49 (0.15) | 66 (6.73) | 32 (13.91) | |
Dose (g/m²) | 3.02 (2.96–4.04) | 3.06 (2.90–4.96) | 3.02 (2.95-4.00) | 3.03 (2.90–4.95) | 0.056 |
Laboratory test | |||||
TBIL (µmol/L) | 9.3 (6.7–12.5) | 10.7 (7.7–14.7) | 9.5 (6.7–12.6) | 10.5 (7.6–14.7) | < 0.001 |
Cr (µmol/L) | 27.0 (22.0–34.0) | 49.0 (37.0-65.5) | 27.0 (22.0–34.0) | 48.0 (37.0-66.3) | < 0.001 |
UA (µmol/L) | 222.0 (187.3–261.0) | 300.0 (245.0-354.5) | 222.0 (189.0-261.0) | 299.5 (241.5–351.0) | < 0.001 |
ALB (g/L) | 45.2 (42.7–47.2) | 43.8 (41.0-46.4) | 45.2 (42.4–47.2) | 43.8 (41.4–46.4) | < 0.001 |
ALT (IU/L) | 20.9 (14.0-40.15) | 17.2 (28.2–58.2) | 20.95 (13.9–38.7) | 25.9 (16.2–55.0) | < 0.001 |
PH | 6.5 (6.0–7.0) | 6.5 (6.0–7.0) | 6.5 (6.0–7.0) | 6.5 (6.0–7.0) | 0.035 |
PCV (%) | 32.6 (30.1–34.7) | 30.8 (27.9–33.2) | 32.5 (29.9–34.6) | 31.1 (28.1–33.4) | < 0.001 |
WBC (109/L) | 3.30 (2.40–4.55) | 4.12 (2.67–5.80) | 3.28 (2.40–4.52) | 4.21 (2.57–6.13) | < 0.001 |
PLT (109/L) | 295.0 (224.0-383.0) | 212.0 (278.0-359.0) | 293.0 (223.0-382.8) | 272.5 (207.8-354.8) | 0.016 |
HGB (g/L) | 107.0 (98.0-114.0) | 102.0 (91.0-111.0) | 108.0 (99.0-114.0) | 102.0 (91.8–112.0) | < 0.001 |
PT (second) | 11.74 (11.20–12.20) | 11.6 (10.8–12.0) | 11.79 (11.20–12.20) | 11.6 (10.8–12.0) | < 0.001 |
LDH (IU/L) | 247.3 (216.7–282.0) | 259.0 (231.3-291.9) | 247.3 (216.3-283.3) | 256.6 (228.7-289.7) | < 0.001 |
FIB (g/L) | 2.29 (1.97–2.70) | 2.37 (2.07–2.80) | 2.29 (1.97–2.70) | 2.37 (2.09–2.80) | 0.001 |
CSF transparency | |||||
Clear | 1342 (95.86) | 321 (97.57) | 936 (95.51) | 223 (96.96) | 0.543 |
Micro-turbidity | 38 (2.71) | 3 (0.91) | 27 (2.76) | 3 (1.30) | |
Turbidity | 18 (1.86) | 5 (1.52) | 15 (1.53) | 4 (1.74) | |
Turbid with clots | 2 (0.14) | 0 (0.00) | 2 (0.20) | 0 (0.00) | |
Pandy’s test | |||||
(-) | 1277 (91.21) | 305 (92.71) | 888 (90.61) | 213 (92.61) | 0.239 |
(±) | 58 (4.14) | 6 (1.82) | 42 (4.29) | 4 (1.74) | |
(+) | 28 (2.0) | 13 (3.95) | 22 (2.24) | 9 (0.39) | |
(++) | 28 (2.0) | 5 (1.52) | 23 (2.35) | 4 (1.74) | |
(+++) | 7 (0.50) | 0 (0.00) | 3 (0.31) | 0 (0.00) | |
(++++) | 2 (0.14) | 0 (0.01) | 2 (0.20) | 0 (0.00) | |
Cl (mg/L) | 122.1 (119.9-124.1) | 122.2 (120.3-124.6) | 122.0 (119.8-124.1) | 122.2 (120.3–124.0) | 0.454 |
Drug combination | |||||
Omeprazole | 48 (3.43) | 57 (17.33) | 28 (2.86) | 36 (15.65) | < 0.001 |
Ofloxacin | 13 (0.93) | 0 (0.00) | 12 (1.22) | 0 (0.00) | 0.189 |
Benzylpenicillin sodium | 7 (0.50) | 2 (0.61) | 4 (0.41) | 2 (0.87) | 0.708 |
Levofloxacin | 13 (0.93) | 0 (0.00) | 12 (1.22) | 0 (0.00) | 0.189 |